A Phase 3 Study to Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD
Part of paid clinical trials in Gilbert, Arizona.
- Sponsor
- Shanghai Henlius Biotech
- Study ID
- NCT04740671
- Phase
- PHASE3
- Status
- Completed
Conditions
- Age Related Macular Degeneration
Eligibility Criteria
- Sex
- ALL
- Age
- 50 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- HLX04-O — DRUGBiologic recombinant anti-VEGF humanized monoclonal antibody, developed by Shanghai Henlius Biotech, Inc.
- ranibizumab — DRUGBiologic anti-VEGF recombinant humanized monoclonal antibody fragment
Study Details
This study will compare the efficacy and safety of HLX04-O administered by intravitreal injection (IVT) with ranibizumab in patients with active wAMD.
Key Dates
- First listed
- Feb 5, 2021
- Start date
- Jul 1, 2021
- Status verified
- Jan 2025
- Primary completion
- Dec 31, 2024
- Completion
- Dec 31, 2024
Study Design
- Enrollment
- 410 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: HLX04-OBiologic recombinant anti-VEGF humanized monoclonal antibody
- Active Comparator: RanibizumabBiologic anti-VEGF recombinant humanized monoclonal antibody fragment
Primary Outcome Measure
Mean change from baseline in BCVA at at Week 36 [ Time Frame: up to at Week 36 ]
Locations (42)
Find similar trials in Gilbert, AZ
Related Studies
- Strategies for Improving Linkage-to-Care After Eye Disease ScreeningRecruiting · University of California, San Francisco · San Francisco, California
- Phase 1 Study of C.001 in Retinal DegenerationPHASE1 · Recruiting · Cellio Therapeutics Inc · Beverly Hills, California